Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
South Korea CNS medicines specialist SK Biopharmaceuticals and twoXAR, a US artificial intelligence (AI)-driven biopharmaceutical company, today announced an agreement to discover and develop first-in-class therapeutics for non-small cell lung cancer (NSCLC). 18 April 2019
In Houston, Texas, scientists at the MD Anderson Cancer Center say they have discovered a new vulnerability in and potential treatment pathway for triple negative breast cancers (TNBC). 18 April 2019
A successful Phase II trial has led Indian pharma company Zydus Cadila to move its HIF-PH inhibitor desidustat into late-stage development. 17 April 2019
Brent Saunders, the chief executive and chairman of Ireland-headquartered drugmaker Allergan, will suddenly be feeling a lot better ahead of the company’s annual meeting of shareholders on May 1. 17 April 2019
Canada-based Canopy Growth is the world’s largest cannabis company, by market cap, and it aspires to be a world leader in developing the drug as a medicine. 17 April 2019
At its annual press conference in Ingelheim, just outside Frankfurt, privately-held drugmaker Boehringer Ingelheim revealed net sales of 17.5 billion euros ($19.8 billion) for 2018, down 3.3% from 18.1 billion euros the year before. 17 April 2019
The Pharmaceutical Price Regulation Scheme (PPRS) is dead; long live the Voluntary Scheme for Branded Medicines Pricing and Access (Voluntary Scheme)! 16 April 2019
Global vaccines producers are losing their positions in the Russian market, due to the ever growing competition with local producers, which receive support from the state, according to recent statements of producers, reports The Pharma Letter’s local correspondent. 16 April 2019
Japan’s largest drugmaker Takeda has officially launched the production of Advate (octocog alfa) - a drug for the treatment of patients with hemophilia A - at the facilities of its Russian partner, the Moscow-based Biocad plant. 16 April 2019
Shares in US healthcare giant Johnson & Johnson were up by nearly 3% after half-an-hour's trading on Tuesday following the company’s quarterly results presentation. 16 April 2019
Financing and creating enduring confidence around a deal like Takeda’s $62 million purchase of Shire is not straight forward, but the Japanese drugmaker has hired one of the best operators in his field to help with the task. 16 April 2019
Chinese drugmaker Hansoh Pharmaceutical Group has re-filed its application for an initial public offering (IPO) in Hong Kong, according to sources quoted by Reuters. 15 April 2019
Johnson & Johnson has unveiled positive Phase III data from the CREDENCE study of Invokana (canagliflozin) at the World Congress of Nephrology in Australia. 15 April 2019
Viking Therapeutics has presented new results from the company's 12-week Phase II study of VK2809 at the International Liver Congress 2019 in Vienna. 12 April 2019
Amid the endless series of headlines about Brexit and Donald Trump, the latest appearance of the Ebola virus has not received the international attention that the previous outbreak did. 12 April 2019
USA-based liver specialist Intercept Pharmaceuticals has presented further Phase III data from the REGENERATE study of obeticholic acid (OCA) in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH). 11 April 2019
AstraZeneca continues to make strides in the company’s vision to advance clinical practice from treating patients with a single disease, such as type-2 diabetes (T2D), to addressing overlapping disease areas and risk factors, such as kidney disease. 11 April 2019
The Economist Intelligence Unit (EIU) has predicted that Russia’s pharma market will grow by nearly 5% in 2019 from 2018, in US dollar terms. 11 April 2019
The Novartis unit Sandoz has signed an agreement with Japanese drugmaker Shionogi for the commercialization of Rizmoic (naldemedine) in Europe. 11 April 2019